Tag: Soft tissue sarcoma

In October 2023, the U.S. Food and Drug Administration (FDA) approved the first generic versions of the targeted cancer therapy Votrient (pazopanib), marking a significant milestone for patients and healthcare providers. This development followed the expiration of key patents, paving the way for more affordable treatment options.

Pazopanib, marketed under the brand name Votrient, has demonstrated significant efficacy in treating specific types of advanced cancers. Approved by the U.S. Food and Drug Administration (FDA) for both advanced renal cell carcinoma and advanced soft tissue sarcoma, this medication is a powerful component of targeted therapy regimens.